`

Adverum Biotechnologies

Biotechnology Research

Specialities :
Gene therapy
Biotechnology
Rare diseases
Ophthalmology
And retina
revenue-icon Revenue
1M - 10M
funding-icon Total Funding
$127.5M
size-icon Size
51 - 200

Frequently Asked Questions About Adverum Biotechnologies

What does Adverum biotechnologies do?+

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet...

What are Adverum biotechnologies's specialties? +

Gene therapy,biotechnology,rare diseases,ophthalmology,and retina

What is Adverum biotechnologies's industry? +

Adverum biotechnologies operates in the Biotechnology research industry.

What is Adverum biotechnologies's revenue? +

Adverum biotechnologies's revenue is 1m - 10m

What is Adverum biotechnologies's company size? +

Adverum biotechnologies has 51 - 200 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.